Beam Therapeutics(US:BEAM)2026-01-12 12:00Financial Position - As of December 31, 2025, Beam Therapeutics estimates its cash, cash equivalents, and marketable securities to be approximately $1.25 billion[6]. - The company is assessing the sufficiency of its capital resources to fund operating expenses and capital expenditures[11]. - The company may receive additional cash consideration related to the acquisition of Orbital Therapeutics by Bristol-Myers Squibb[11]. - The financial results for the fourth quarter and fiscal year ended December 31, 2025, are still being finalized and are subject to completion of financial statement closing procedures[7]. - The company cautions that its estimated cash balance is preliminary and should not be relied upon without further context regarding its financial condition[7]. Corporate Developments - The company announced progress across its base editing portfolio and outlined key anticipated milestones in a press release dated January 11, 2026[9]. - Beam Therapeutics plans to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, showcasing its corporate presentation[9]. Research and Development - The company is focused on developing life-long, curative, precision genetic medicines through base editing technology[11]. - Beam Therapeutics is evaluating therapeutic applications for its technology, including Sickle Cell Disease (SCD), Alpha-1 Antitrypsin Deficiency (AATD), and Glycogen Storage Disease Type 1a (GSD1a)[11]. - The company anticipates potential regulatory interactions and filings related to its clinical trials for product candidates such as risto-cel, BEAM-103, BEAM-301, and BEAM-302[11].